Abstract
Quinolones provide a cost-effective treatment option for infection because the availability of potent oral formulations facilitates early conversion from IV to oral therapy, with resultant cost savings compared with standard courses of IV therapy. The newer generations of extended-spectrum quinolones are likely to increase the potential cost savings that can be achieved by early IV-to-oral switch therapy, delegates were told at the 32nd Annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP) [Atlanta, Georgia, US; December 1997]. However, care must be taken to ensure that inappropriate use of these new antibacterial agents does not compromise their utility.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
